Radioactive Antibody Labeling Facility (RALF)

Radiolabeling Facility Functions

The Radiolabeling Facility is equipped to handle radiolabeling of proteins, peptides, and small organic molecules at 100 mCi levels for most radionuclides and for selected radionuclides up to 1 Ci. Synthetic chemistry and radiochemistry are established for several biologics and small molecules, and can be modified to accommodate variety of molecules for the introduction of:

Radiohalides: 123I, 124I, 125I, 131I, 76Br, 211At, 18F

Radiometals: 111In, 90Y, 86Y, 177Lu, 64Cu, 99mTc, 153Gd, 68Ga

Purification and Quality Assurance:
Facility is equipped to provide a variety of the purification and quality assurance protocols including analytical and semi-preparative HPLC with radioactivity, UV, and fluorescence detection, ITLC, LC, and TLC.

Standard operating quality assurance protocols are already set up for several proteins, peptides, antibodies, and small molecules. New protocols can be prepared and tested at the request of the investigator.

Clinical Services:
The Facility provides radiolabeling services to the UNMC clinical research community from the pre-phase I through the expanded access clinical trials. Over 30 clinical trials were completed with the support of the Facility. The total number of doses prepared exceeds 1,000 (~52.5 Ci).

Disease

Diagnostic Isotope

Treatment Isotope

Disease

Diagnostic Isotope

Treatment Isotope

Pancreatic cancer

In-111
I-131

Y-90
I-131

Bladder cancer

I-123

I-125

Ovarian cancer

I-125
I-123
Tc-99m

I-125

Hodgkin’s disease

In-111

Y-90

Colon cancer

I-131
In-111
I-123

I-131
Y-90

Non-Hodgkin’s lymphoma

I-131
Tc-99m
In-111

I-131
Y-90

Periampullary cancer

I-131

I-131

Colorectal cancer

Tc-99m

 

Rectal cancer

I-131

I-131

Hepatic metastases

Tc-99m
I-123

 

Appendiceal carcinoma

In-111

Y-90

Head and neck carcinoma

In-111

Y-90

Esophageal cancer

In-111

Y-90

Bladder cancer

I-123

I-125

Pre-clinical and translational services:
Facility also conducts radioactive drug development studies:

  • Novel ASGPR-seeking reagents for the assessment of liver function are developed and tested in mice and nonhuman primates (>50 studies in cynomolgus monkeys).
  • New theranostics are developed and tested in mice for imaging and therapy of prostate, ovarian, breast, pancreatic and brain cancers.
  • Diagnostic radiopharmaceuticals for the early detection of AD and for the longitudinal imaging of AD response to treatment are tested in AD mice.
  • Radiolabeled microbubbles are tested in pigs.

image

image

;